Loading
Nanoplatforms for Cancer Theranostics · Journal article
Advanced Science · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a proof-of-concept preclinical study describing a gallium-based liquid metal nanoparticle engineered to deplete regulatory T cells, deliver photothermal therapy, and activate STING signalling in murine triple-negative breast cancer models. The work demonstrates mechanism-of-action and tumour control in mice but provides no human safety, efficacy, or comparative data; translation to clinical use remains speculative.
Preclinical in vivo animal study. Murine 4T1 orthotopic and metastatic triple-negative breast cancer models.. Intervention: Blood cell-camouflaged liquid metal nanoconjugate (B-LM-DMX-αCD25) combining gallium-based liquid metal photothermal core, anti-CD25 antibody, and STING agonist (5,6-dimethylxanthenone-4-acetic acid) with near-infrared irradiation..
Quantitative RT-PCR of 13 immune-related genes confirmed STING engagement, robust CD8+ cytotoxic T-cell infiltration, and Treg depletion in treated tumors Near-infrared-triggered photothermal therapy achieved 58°C within 5 minutes In orthotopic 4T1 models, the nanoplatform achieves significant tumor regression with enhanced survival
No human data, toxicology studies, or pharmacokinetic profiles reported
This nanoplatform concept addresses immunosuppression in TNBC through a novel triple mechanism; however, preclinical efficacy in mice does not predict human safety or efficacy. Clinicians and researchers should await in vitro validation, pharmacokinetic studies, and regulatory assessment before considering clinical translation.
Early-stage preclinical work in animal models demonstrating a novel nanoparticle platform with mechanistic activity; lacks human data, direct clinical comparators, and independent replication required for clinical translation claims.
As stated by the source record.
Quoted from the source exactly as published.
This nanoplatform concept addresses immunosuppression in TNBC through a novel triple mechanism; however, preclinical efficacy in mice does not predict human safety or efficacy. Clinicians and researchers should await in vitro validation, pharmacokinetic studies, and regulatory assessment before considering clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Triple-negative breast cancer (TNBC) remains highly lethal due to aggressive metastasis and profound immunosuppression by regulatory T cells (Tregs). Here, we present a biomimetic liquid metal (LM)-based photothermal immunotherapeutic nanoplatform exploiting gallium-based LMs to orchestrate cascade amplification of antitumor immunity. The engineered nanoplatform (B-LM-DMX-αCD25) integrates an LM photothermal core with dual immunomodulatory components-anti-CD25 antibody for Treg depletion and stimulator of interferon genes (STING) agonist 5,6-dimethylxanthenone-4-acetic acid (DMX) for innate immune activation-while blood-derived camouflaging enhances immune evasion and tumor accumulation. Quantitative RT-PCR of 13 immune-related genes confirmed STING engagement, robust CD8+ cytotoxic T-cell infiltration, and Treg depletion in treated tumors. This platform operates through three synchronized mechanisms: (1) selective intratumoral Treg depletion dismantling immunosuppression; (2) near-infrared-triggered LM-mediated photothermal therapy (58°C within 5 min) inducing immunogenic cell death and releasing tumor-associated antigens; and (3) STING pathway activation promoting dendritic cell maturation and tumor-specific cytotoxic T-cell responses, collectively transforming immunologically "cold" TNBC into immune-responsive tumors. In orthotopic 4T1 models, the nanoplatform achieves significant tumor regression with enhanced survival, while in metastatic models, it reduces pulmonary metastatic nodules and extends median survival beyond 70 days. This work establishes a paradigm-shifting biomimetic LM-based nanodelivery strategy addressing fundamental immunological barriers in TNBC through coordinated photothermal-immunotherapy, offering a clinically translatable approach for TNBC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.